直接作用抗病毒药物治疗丙型肝炎肝硬化中新发肝细胞癌的发生率。

IF 1.2 Q4 ONCOLOGY Hepatic Oncology Pub Date : 2018-07-25 eCollection Date: 2018-01-01 DOI:10.2217/hep-2018-0003

Gabriela Kuftinec, Thomas Loehfelm, Michael Corwin, Blythe Durbin-Johnson, MarieChristi Candido, Rebecca Hluhanich, Souvik Sarkar

{"title":"直接作用抗病毒药物治疗丙型肝炎肝硬化中新发肝细胞癌的发生率。","authors":"Gabriela Kuftinec, Thomas Loehfelm, Michael Corwin, Blythe Durbin-Johnson, MarieChristi Candido, Rebecca Hluhanich, Souvik Sarkar","doi":"10.2217/hep-2018-0003","DOIUrl":null,"url":null,"abstract":"Aim: Recent studies raise concerns for higher incidence of hepatocellular carcinoma (HCC) after direct-acting antiviral therapy for hepatitis C virus (HCV).Methods: In this study, using analysis of liver imaging pre- and post-DAA treatment, we queried new occurrence or 'de novo' of HCC in patients with HCV-cirrhosis treated with DAAs. Of 150 patients who met study criteria, 7 (4.7%; 95% CI: 2.1-9.5%) patients developed de novo HCC which did not differ from historical rates of 3% (p = 0.22).Results: Notably, patients with decompensated cirrhosis had significantly higher rate of de novo HCC (9.3%; 95% CI: 3.12-22.2%; p = 0.04).Conclusion: Our data support the need for continued surveillance for HCC in HCV cirrhotics even after successful therapy.","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"5 1","pages":"HEP06"},"PeriodicalIF":1.2000,"publicationDate":"2018-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/hep-2018-0003","citationCount":"6","resultStr":"{\"title\":\"De novo hepatocellular carcinoma occurrence in hepatitis C cirrhotics treated with direct-acting antiviral agents.\",\"authors\":\"Gabriela Kuftinec, Thomas Loehfelm, Michael Corwin, Blythe Durbin-Johnson, MarieChristi Candido, Rebecca Hluhanich, Souvik Sarkar\",\"doi\":\"10.2217/hep-2018-0003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Aim: Recent studies raise concerns for higher incidence of hepatocellular carcinoma (HCC) after direct-acting antiviral therapy for hepatitis C virus (HCV).Methods: In this study, using analysis of liver imaging pre- and post-DAA treatment, we queried new occurrence or 'de novo' of HCC in patients with HCV-cirrhosis treated with DAAs. Of 150 patients who met study criteria, 7 (4.7%; 95% CI: 2.1-9.5%) patients developed de novo HCC which did not differ from historical rates of 3% (p = 0.22).Results: Notably, patients with decompensated cirrhosis had significantly higher rate of de novo HCC (9.3%; 95% CI: 3.12-22.2%; p = 0.04).Conclusion: Our data support the need for continued surveillance for HCC in HCV cirrhotics even after successful therapy.\",\"PeriodicalId\":44854,\"journal\":{\"name\":\"Hepatic Oncology\",\"volume\":\"5 1\",\"pages\":\"HEP06\"},\"PeriodicalIF\":1.2000,\"publicationDate\":\"2018-07-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.2217/hep-2018-0003\",\"citationCount\":\"6\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hepatic Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2217/hep-2018-0003\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2018/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hepatic Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/hep-2018-0003","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2018/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 6

摘要

目的:最近的研究引起了对丙型肝炎病毒(HCV)直接抗病毒治疗后肝细胞癌(HCC)发生率增高的关注。方法:在本研究中，通过分析daa治疗前后的肝脏影像学，我们询问肝细胞癌新发或“新生”的hcv -肝硬化患者接受daa治疗。在150例符合研究标准的患者中，7例(4.7%;95% CI: 2.1-9.5%)，与历史发生率3% (p = 0.22)无差异。结果:值得注意的是，失代偿期肝硬化患者的新发HCC发生率明显较高(9.3%;95% ci: 3.12-22.2%;p = 0.04)。结论:我们的数据支持HCV肝硬化患者即使在治疗成功后仍需要继续监测HCC。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

摘要图片

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

De novo hepatocellular carcinoma occurrence in hepatitis C cirrhotics treated with direct-acting antiviral agents.

Aim: Recent studies raise concerns for higher incidence of hepatocellular carcinoma (HCC) after direct-acting antiviral therapy for hepatitis C virus (HCV).

Methods: In this study, using analysis of liver imaging pre- and post-DAA treatment, we queried new occurrence or 'de novo' of HCC in patients with HCV-cirrhosis treated with DAAs. Of 150 patients who met study criteria, 7 (4.7%; 95% CI: 2.1-9.5%) patients developed de novo HCC which did not differ from historical rates of 3% (p = 0.22).

Results: Notably, patients with decompensated cirrhosis had significantly higher rate of de novo HCC (9.3%; 95% CI: 3.12-22.2%; p = 0.04).

Conclusion: Our data support the need for continued surveillance for HCC in HCV cirrhotics even after successful therapy.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Hepatic Oncology ONCOLOGY-

CiteScore

0.40

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Primary liver cancer is the sixth most common cancer in the world, and the third most common cause of death from malignant disease. Traditionally more common in developing countries, hepatocellular carcinoma is becoming increasingly prevalent in the Western world, primarily due to an increase in hepatitis C virus infection. Emerging risk factors, such as non-alcoholic fatty liver disease and obesity are also of concern for the future. In addition, metastatic tumors of the liver are more common than primary disease. Some studies report hepatic metastases in as many as 40 to 50% of adult patients with extrahepatic primary tumors. Hepatic Oncology publishes original research studies and reviews addressing preventive, diagnostic and therapeutic approaches to all types of cancer of the liver, in both the adult and pediatric populations. The journal also highlights significant advances in basic and translational research, and places them in context for future therapy. Hepatic Oncology provides a forum to report and debate all aspects of cancer of the liver and bile ducts. The journal publishes original research studies, full reviews and commentaries, with all articles subject to independent review by a minimum of three independent experts. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal''s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3.